Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

FTC Seeks to Block Amgen's Acquisition of Horizon Therapeutics: What's Next for Both Stocks?: https://g.foolcdn.com/editorial/images/732729/handshake-broken.jpg
FTC Seeks to Block Amgen's Acquisition of Horizon Therapeutics: What's Next for Both Stocks?

Deal or no deal? That's now the big question for investors concerning Amgen's (NASDAQ: AMGN) pending $28 billion acquisition of Horizon Therapeutics (NASDAQ: HZNP).

The Federal Trade Commission

Is This Dow Jones Stock a Buy for Income Investors?: https://g.foolcdn.com/editorial/images/732584/a-doctor-examines-a-patient.jpg
Is This Dow Jones Stock a Buy for Income Investors?

Income investing is a tried-and-true investing strategy. This is because businesses that pay consistent and growing dividends to shareholders are often mature businesses that can't possibly reinvest

The FTC Wants to Block the $28 Billion Amgen-Horizon Therapeutics Deal: https://g.foolcdn.com/editorial/images/732811/featured-daily-upside-image.jpg
The FTC Wants to Block the $28 Billion Amgen-Horizon Therapeutics Deal

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.

Big Pharma needs

Which Is the Better Forever Stock: Johnson & Johnson or UnitedHealth Group?: https://g.foolcdn.com/editorial/images/732093/adaptimmune.jpg
Which Is the Better Forever Stock: Johnson & Johnson or UnitedHealth Group?

Johnson & Johnson (NYSE: JNJ) and UnitedHealth Group (NYSE: UNH) are considered great healthcare stocks to hold for the long term because of their size, steady cash flow, and above-average

These 2 Pharma Stocks Might Face Off Soon -- but They Could Both Win: https://g.foolcdn.com/editorial/images/732171/neurologist-shows-patient-a-brain-scan-image.jpg
These 2 Pharma Stocks Might Face Off Soon -- but They Could Both Win

Eli Lilly (NYSE: LLY) and Biogen (NASDAQ: BIIB) are both keen to compete in the market for Alzheimer's disease therapies. Biogen's prior attempt at an Alzheimer's medicine to hit the market was a

3 Reasons to Buy Biogen Stock (and 1 to Sell): https://g.foolcdn.com/editorial/images/731364/a-doctor-looking-at-a-tablet-with-another-person.jpg
3 Reasons to Buy Biogen Stock (and 1 to Sell)

Biogen (NASDAQ: BIIB) has been a polarizing stock to own over the past few years. Aduhelm's accelerated approval sent the stock soaring a few years ago, but after controversy surrounding its

Which Is the Safer Dividend Stock: Stryker or Medtronic?: https://g.foolcdn.com/editorial/images/731701/doctors-having-a-meeting-with-administrator-in-a-hospital.jpg
Which Is the Safer Dividend Stock: Stryker or Medtronic?

Stryker (NYSE: SYK) and Medtronic (NYSE: MDT) are a pair of the biggest and most important medical-device and supply companies out there, but they're a bit different in the stability of the dividend

Why These 3 Nasdaq Stocks Were Glowing Green This Week: https://g.foolcdn.com/editorial/images/732173/chalk.jpg
Why These 3 Nasdaq Stocks Were Glowing Green This Week

Despite another less-than-stellar Consumer Price Index report and more volatility among regional bank stocks, growth equities, on balance, were on the upswing this week. The tech-heavy Nasdaq

Here's Why Eli Lilly's Alzheimer's Drug Could Be the Real Deal: https://g.foolcdn.com/editorial/images/731368/a-group-of-scientists-looking-at-a-report.jpg
Here's Why Eli Lilly's Alzheimer's Drug Could Be the Real Deal

Eli Lilly (NYSE: LLY) has a potential Alzheimer's treatment in donanemab that shows a lot of promise. The company reported data from a recent trial which demonstrated some encouraging results, and

3 Things About Medtronic That Smart Investors Know: https://g.foolcdn.com/editorial/images/730572/doctors-having-a-meeting-with-administrator-in-a-hospital.jpg
3 Things About Medtronic That Smart Investors Know

Medtronic (NYSE: MDT) is a massive business that's changing rapidly now to keep up with shifts in its markets and an evolving global economy -- all of which can make it a bit difficult for observers

This FDA Nod Is a Game Changer for Patients: Could It Equal Billions for Vertex Pharmaceuticals?: https://g.foolcdn.com/editorial/images/732048/baby_newborn_with-dad.jpg
This FDA Nod Is a Game Changer for Patients: Could It Equal Billions for Vertex Pharmaceuticals?

Vertex Pharmaceuticals (NASDAQ: VRTX) is already a rock star in the world of cystic fibrosis (CF) treatment. The company's drugs have been life-changing for children and adults living with the

2 Cathie Wood Stocks That Can Get You Through Any Recession: https://g.foolcdn.com/editorial/images/731022/physician-giving-a-high-five-to-a-young-patient.jpg
2 Cathie Wood Stocks That Can Get You Through Any Recession

Economists at the U.S. Federal Reserve recently uttered the dreaded "R" word. They are now predicting a recession will come later this year. Investors have been bracing for this possibility for a

Why CRISPR Therapeutics Stock Is on Fire Today: https://g.foolcdn.com/editorial/images/731718/pig-taking-flight.jpg
Why CRISPR Therapeutics Stock Is on Fire Today

Shares of the developmental gene-editing company CRISPR Therapeutics (NASDAQ: CRSP) were up by 12.4% on sky-high volume as of 1:46 p.m. ET Tuesday afternoon. The big gain came in response to the bio

Is Medtronic Stock a Buy Now?: https://g.foolcdn.com/editorial/images/731193/gettyimages-904880170.jpg
Is Medtronic Stock a Buy Now?

Medtronic (NYSE: MDT) is on a roll in more than one way. The medical device giant is beating the S&P 500 since the start of 2023. The company also continues to strengthen its portfolios, winning

1 Soaring Growth Stock That's Still an Unbeatable Bargain: https://g.foolcdn.com/editorial/images/730516/investor-individual-stock-charts-getty.jpg
1 Soaring Growth Stock That's Still an Unbeatable Bargain

Are you looking for underappreciated growth stocks that can deliver big gains? Try starting your search in the rapidly growing industry for minimally invasive cosmetic procedures.

The global market

1 Relatively Safe Dividend Growth Stock to Buy Hand Over Fist Right Now: https://g.foolcdn.com/editorial/images/729512/businessmen-and-doctors-working-on-touchpad-in-a-hospital.jpg
1 Relatively Safe Dividend Growth Stock to Buy Hand Over Fist Right Now

If you can buy high-quality dividend stocks when other investors sour on them, you can plant the seeds for robust returns in the future. And that's exactly why it might be worth buying shares of

Looking for Steady, Passive Income? Buy AbbVie Stock: https://g.foolcdn.com/editorial/images/730634/a-doctor-and-patient-talk-to-each-other-during-an-appointment.jpg
Looking for Steady, Passive Income? Buy AbbVie Stock

Dividend growth investing revolves around selecting only the most reliable businesses for your portfolio. This can be measured by consecutive years of dividend growth.

With 51 consecutive years of

Better Gene Sequencing Stock: Illumina vs. Bionano Genomics: https://g.foolcdn.com/editorial/images/729509/two-scientists-work-at-lab-bench-with-scope.jpg
Better Gene Sequencing Stock: Illumina vs. Bionano Genomics

Illumina (NASDAQ: ILMN) and Bionano Genomics (NASDAQ: BNGO) might both make gene sequencing devices, but as investments the two couldn't be more different. Whereas Bionano is a new entrant to the

Why Illumina Fell 11.6% in April: https://g.foolcdn.com/editorial/images/731339/genetic-sequencing.jpg
Why Illumina Fell 11.6% in April

Shares of Illumina (NASDAQ: ILMN) fell by 11.6% in April, according to data provided by S&P Global Market Intelligence.

The fall means that shares of the gene-sequencing company have only inched up

3 Great Income Stocks That Retirees Should Love: https://g.foolcdn.com/editorial/images/731008/happy-older-couple-retirement-wealth-invest.jpg
3 Great Income Stocks That Retirees Should Love

Most Americans don't have to wait until they're retired to know that Social Security benefits won't be enough to maintain their current lifestyle. If they pay any attention to retirement planning

Cigna Group (CI) Q1 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
Cigna Group (CI) Q1 2023 Earnings Call Transcript

Image source: The Motley Fool.

Cigna Group (NYSE: CI)Q1 2023 Earnings CallMay 05, 2023, 8:30 a.m. ET

Operator

Continue reading

Source Fool.com

2 Magnificent Dividend Stocks to Buy Before the Next Recession: https://g.foolcdn.com/editorial/images/730574/elderly-person-sitting-on-a-bed.jpg
2 Magnificent Dividend Stocks to Buy Before the Next Recession

Fears of a coming recession are probably about as high right now as they have been over the past year. That's because the U.S. Federal Reserve recently predicted an economic downturn would descend

Vaccine Sales Are Falling. Should You Still Buy Pfizer?: https://g.foolcdn.com/editorial/images/730746/gettyimages-1252566534.jpg
Vaccine Sales Are Falling. Should You Still Buy Pfizer?

Pfizer (NYSE:PFE) confirmed this week what everyone has been expecting. COVID-19 vaccine sales are falling drastically. The company reported a 77% drop in Comirnaty sales in the first quarter

Why Regeneron Pharmaceuticals Stock Is Tanking Today: https://g.foolcdn.com/editorial/images/730998/crashing-arrow.jpg
Why Regeneron Pharmaceuticals Stock Is Tanking Today

Regeneron Pharmaceuticals (NASDAQ: REGN), a large-cap biotechnology company, is under heavy pressure today. Specifically, the biotech's stock was down by an unsightly 6.5% on heavy volume as of

Zoetis (ZTS) Q1 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
Zoetis (ZTS) Q1 2023 Earnings Call Transcript

Image source: The Motley Fool.

Zoetis (NYSE: ZTS)Q1 2023 Earnings CallMay 04, 2023, 8:30 a.m. ET

Operator

Continue reading

Source Fool.com